Search Results

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.

ProteoNic Biotechnology BVtoday announced that it has licensed its 2G UNic™ technology for boosting recombinant protein production to the pharmaceutical company Bayer.

Proteon Therapeutics, Inc., a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, announced its financial results for the quarter ended September 30, 2019, and recent events.

Proteon Therapeutics, based in Waltham, Mass., announced that its PATENCY-2 Phase III clinical trial of vonapanitase in chronic kidney disease (CKD) failed to meet its co-primary endpoints.

Eli Lilly and Co. has licensed 2G UNic technology from Leiden, the Netherlands-based ProteoNic Biotechnology BV. The tech is used to improve recombinant protein production. No financial details were disclosed.

Proteon Therapeutics, Inc. announced a long-term contract extension with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase’s active pharmaceutical ingredient (API).

In the third quarter, Proteon raised gross proceeds of $22.0 million.

Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager antibodies for cancer, announced today that it has licensed from ProteoNic BV its 2G UNic™ technology for boosting recombinant protein production, allowing for cost-effective manufacturing at large scale

Under the agreement, Lilly gains non-exclusive commercial rights for application of the technology to the development of proprietary products.